NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis → My top 100 stocks… (From DTI) (Ad) Free TTNP Stock Alerts $7.09 +0.12 (+1.72%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$6.75▼$8.0050-Day Range$6.49▼$9.4152-Week Range$5.00▼$16.60Volume10,649 shsAverage Volume5,128 shsMarket Capitalization$6.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media Get Titan Pharmaceuticals alerts: Email Address Ad DTIMy top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.Get some cool freebies right here. About Titan Pharmaceuticals Stock (NASDAQ:TTNP)Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.Read More TTNP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTNP Stock News HeadlinesApril 23, 2024 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Stock Price Passes Below Two Hundred Day Moving Average of $7.17April 23, 2024 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.comApril 27, 2024 | Prosper Trading Academy (Ad)This AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?March 2, 2024 | uk.investing.comTitan Pharmaceuticals Inc (TTNP)February 20, 2024 | au.finance.yahoo.comTitan Pharmaceuticals, Inc. (TN70.F)February 3, 2024 | morningstar.comTitan Pharmaceuticals Inc TTNPJanuary 26, 2024 | finanznachrichten.deTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing CriteriaJanuary 25, 2024 | finance.yahoo.comTitan Pharmaceuticals Fully Compliant With NASDAQ Listing CriteriaApril 27, 2024 | Prosper Trading Academy (Ad)This AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?January 10, 2024 | benzinga.comTitan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and DatesDecember 29, 2023 | finanznachrichten.deTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and RatioDecember 28, 2023 | washingtonpost.comBarbie, the Titan submersible and everything else we Googled in 2023December 28, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Reverse Stock Split and RatioOctober 16, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of DirectorsSeptember 18, 2023 | seekingalpha.comTitan Pharmaceuticals reports $9.5M private placement of convertible preferred stockSeptember 18, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred StockAugust 28, 2023 | finance.yahoo.comUnveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive GuideAugust 13, 2023 | thestreet.comTitan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment ApprovalJuly 27, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Sale of Certain ProNeura AssetsJune 29, 2023 | usatoday.comPatents, lawsuits, safety concerns — then tragedy. A timeline of OceanGate's Titan sub.May 26, 2023 | finance.yahoo.comTTNP - Titan Pharmaceuticals, Inc.May 23, 2023 | sports.yahoo.comWatch: Prowling tiger bows to ‘titan herd’ of elephantsMarch 22, 2023 | seekingalpha.comTTNP Titan Pharmaceuticals, Inc.December 15, 2022 | finance.yahoo.comTitan Pharmaceuticals Provides Shareholder UpdateDecember 12, 2022 | nz.finance.yahoo.comTitan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.November 21, 2022 | bizjournals.comChapel Hill surgical tech company shapes plan to keep Nasdaq listingNovember 17, 2022 | finance.yahoo.comTitan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)See More Headlines Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/30/2021Today4/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TTNP CUSIPN/A CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees4Year Founded1992Profitability EPS (Most Recent Fiscal Year)($8.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,570,000.00 Net Margins-2,014.71% Pretax Margin-3,026.63% Return on Equity-165.90% Return on Assets-105.75% Debt Debt-to-Equity RatioN/A Current Ratio5.55 Quick Ratio5.55 Sales & Book Value Annual Sales$180,000.00 Price / Sales35.84 Cash FlowN/A Price / Cash FlowN/A Book Value$8.82 per share Price / Book0.80Miscellaneous Outstanding Shares910,000Free Float686,000Market Cap$6.45 million OptionableOptionable Beta1.33 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David Elliot Lazar (Age 33)CEO & Principal Financial Officer Comp: $1.42MDr. Katherine L. Beebe-DeVarney Ph.D. (Age 63)President, COO & Director Comp: $462kMr. Mike FritzNational Sales DirectorJennifer KiernanExecutive Assistant to CEO & Investor Communications CoordinatorJoe SchreiExecutive Director of Commercial OperationsKey CompetitorsCreative Medical TechnologyNASDAQ:CELZBrickell BiotechNASDAQ:BBIChromocell TherapeuticsNYSE:CHROFresh Tracks TherapeuticsNASDAQ:FRTXPalisade BioNASDAQ:PALIView All CompetitorsInsidersDavid E. LazarSold 169,445 sharesTotal: $4.17 M ($24.60/share)View All Insider Transactions TTNP Stock Analysis - Frequently Asked Questions How have TTNP shares performed in 2024? Titan Pharmaceuticals' stock was trading at $8.25 at the beginning of the year. Since then, TTNP stock has decreased by 14.1% and is now trading at $7.09. View the best growth stocks for 2024 here. Are investors shorting Titan Pharmaceuticals? Titan Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 10,200 shares, an increase of 161.5% from the March 31st total of 3,900 shares. Based on an average trading volume of 10,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.7% of the company's shares are sold short. View Titan Pharmaceuticals' Short Interest. When is Titan Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TTNP earnings forecast. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($17.20) earnings per share for the quarter, beating the consensus estimate of ($26.60) by $9.40. Titan Pharmaceuticals had a negative net margin of 2,014.71% and a negative trailing twelve-month return on equity of 165.90%. When did Titan Pharmaceuticals' stock split? Shares of Titan Pharmaceuticals reverse split on Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI). How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TTNP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressProtect Your Bank Account Before It’s Too LateWeiss RatingsJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
